Reuters: Regulatory News: UPDATE 1-FDA extends review for Salix diarrhea drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-FDA extends review for Salix diarrhea drug Apr 30th 2012, 19:10 April 30 | Mon Apr 30, 2012 3:10pm EDT April 30 (Reuters) - Salix Pharmaceuticals Ltd said U.S. health regulators have extended the review date by three months for its experimental pill for HIV therapy-related diarrhea. The U.S. Food and Drug Administration was to review the drug, crofelemer, on June 5. The FDA has notified Salix that it requires additional time for a full review but did not seek any additional studies, the company said in a statement. Salix holds the North American and European rights to the drug. India's Glenmark Pharmaceuticals Ltd holds the rights to sell the drug in 140 other countries but is in arbitration to retain them after initial developer U.S.-based Napo Pharamaceuticals Inc terminated their agreement in November. Shares of Salix Pharmaceuticals were trading down about 3 percent at $49.28 on Monday afternoon trade on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions